Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2B dose-ranging trial of afimkibart (PF-06480605) in moderate to severe ulcerative colitis
jRCT2080225315Phase 2Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of afimkibart in autoimmune colitis (4 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Clinical remission during induction. Started Aug 2020; status: completed.
02
Drugs
afimkibart
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2080225315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225315.